震撼88.5亿美金！天价创新药BD点火，520880摸高2.75%，港股通医疗ETF（159137）五连阳！机构提示低位机遇

Group 1 - The Hong Kong stock market experienced a comprehensive rebound on February 9, with the pharmaceutical sector continuing its recovery trend, led by Innovent Biologics, which secured an $8.85 billion BD deal, resulting in a peak increase of 8.55% and a closing rise of 7.42% [1][3] - Other leading stocks such as BeiGene rose over 3%, while CSPC Pharmaceutical, China Biologic Products, and 3SBio also saw collective gains [1][3] - The Hong Kong Stock Connect Innovation Drug ETF (520880) opened high, reaching an increase of 2.75% and closing up 1.77%, successfully maintaining an upward trend and surpassing the 10-day moving average with a total transaction volume of 381 million yuan [1][3] Group 2 - On the evening of February 8, Innovent Biologics announced a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, receiving an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [3] - The total transaction scale for China's innovative drug License-out is expected to reach a record $135.7 billion by 2025, with significant collaborations emerging in 2026, including major deals involving CSPC and AstraZeneca ($18.5 billion) and Rongchang and AbbVie ($5.6 billion), validating the global value of domestic innovative drug pipelines [3] - According to Open Source Securities, the Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," entering a commercialization harvest period, with many quality targets showing significant valuation attractiveness after nearly two quarters of correction [3] Group 3 - The Hong Kong Stock Connect medical sector showed active performance, particularly in AI medical and brain-computer interface concept stocks, with major players like JD Health, Alibaba Health, and Ping An Good Doctor all rising around 3% [3] - The AI medical sector is rapidly penetrating the consumer end, expanding application scenarios from smart consultations to chronic disease management, leading to a revaluation of internet medical platforms like Alibaba Health and JD Health [3] Group 4 - CITIC Securities noted that the overall innovation attribute of the Hong Kong medical device sector is strong, with some companies' innovative products having potential for license-out or acquisition [5] - The fundamentals of most companies in the industry are continuously improving, highlighting the investment value of low valuations [5] - It is anticipated that Mindray Medical and Caresyntax will be listed in Hong Kong this year, potentially increasing investment opportunities in the Hong Kong medical device sector [5]